

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.*



## **CHINA BIOTECH SERVICES HOLDINGS LIMITED**

**中國生物科技服務控股有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock code: 8037)**

### **COMPLETION OF ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE**

Reference is made to the announcement of China Biotech Services Holdings Limited (the “**Company**”) dated 20 December 2022 (the “**Announcement**”) in relation to the issue of convertible bonds under general mandate. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

### **COMPLETION OF SUBSCRIPTION AND ISSUE OF CONVERTIBLE BONDS**

The Board is pleased to announce that all the conditions precedent of the Subscription Agreement have been fulfilled and completion of the Subscription took place on 30 December 2022. Accordingly, the Convertible Bonds in the principal amount of US\$10,000,000 have been issued by the Company to the Subscriber on 30 December 2022.

The Existing CB was surrendered and cancelled upon Completion.

Details of the net proceeds from the Subscription, the proposed use of net proceeds and the Subscriber were disclosed in the Announcement.

## EFFECTS ON SHAREHOLDING STRUCTURE OF THE COMPANY

Set out below are (i) the shareholding structure of the Company as at the date of this announcement; (ii) the shareholding structure of the Company assuming full exercise of the conversion rights attached to the Convertible Bonds at the initial Conversion Price of HK\$1.45 per Conversion Share and at the exchange rate of HK\$7.85 to US\$1.00:

Shareholders	(a) As at the date of this announcement		(b) Immediately after the allotment and issue of the Conversion Shares upon exercise of the conversion rights under the Convertible Bonds in full	
	No. of Shares	Approximate %	No. of Shares	Approximate %
Genius Lead (Note 1)	529,500,546	54.97	529,500,546	52.05
Subscriber (Note 2)	–	–	54,137,931	5.32
Other public Shareholders	433,730,604	45.03	433,730,604	42.63
Total	<u>963,231,150</u>	<u>100.00</u>	<u>1,017,369,081</u>	<u>100.00</u>

### Notes:

1. These Shares are held by Genius Lead, which in turn is wholly-owned by Genius Earn Limited, which is in turn wholly-owned by Mr. Liu. As such, Mr. Liu is deemed to be interested in the Shares held by Genius Lead.
2. The Existing CB in the outstanding principal amount of US\$5 million was surrendered and cancelled upon Completion.

## RELEASE OF THE SHARE CHARGE AND DISCHARGE OF THE CORPORATE GUARANTEE AND THE INDIVIDUAL GUARANTEE

The Subscriber delivered to the Company a deed executed on 30 December 2022 confirming the release of the Share Charge and discharge of both the Corporate Guarantee and the Individual Guarantee.

By order of the Board  
**China Biotech Services Holdings Limited**  
**Liu Xiaolin**  
*Chairman and Executive Director*

Hong Kong, 30 December 2022

*As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at [www.hkexnews.hk](http://www.hkexnews.hk) for at least 7 days from the date of its publication and on the website of the Company at [www.cbshhk.com](http://www.cbshhk.com).*